滋髓生血胶囊治疗慢性再生障碍性贫血

目的:探讨滋髓生血胶囊治疗慢性再生障碍性贫血的临床疗效。方法:64例慢性再生障碍性贫血患者,根据随机数字法,分为对照组(环孢菌素A及安雄治疗)和观察组(对照组治疗的基础上,加用滋髓生血胶囊),每组各32例,观察和比较两组临床疗效、治疗前后两组血红蛋白(Hb),白细胞(WBC),血小板(PLT)变化情况,以及治疗期间两组不良反应。结果:与对照组相比,观察组治疗的总有效率明显提高(81.25%VS 56.25%,P0.05);与对照组相比,观察组中医证候的总有效率明显提高(96.875%VS 78.125%,P0.05);与对照组相比,观察组治疗后Hb(80.32±21.27 VS 69.78±20.13)g·L-1,WBC(3.92±1.11 VS 3.14±1.08)×109/L,PLT(46.37±14.32 VS 31.08±13.82)×109/L水平显著提高(P0.05);与对照组相比,观察组多毛症(6.25%VS 28.125%),手颤(12.50%VS 37.50%),牙龈增生(6.25%VS 25.00%)等并发症的发生率显著降低(P0.05)。结论:滋髓生血胶囊治疗慢性再生障碍性贫血的疗效显著、不良反应少,明显改善患者的血象指标,值得临床推广。

Zisui Shengxue Capsule in Treatment of Chronic Aplastic Anemia

Objective: To study the clinical efficacy of Zisui Shengxue capsule in the treatment of chronic aplastic anemia. Method: Totally 64 patients with chronic aplastic anemia were randomized into the control group (treated with cyclosporin A and andriol) and the observation group (given Zisui Shengxue capsule beside the therapy for the control group) according to the random number method, with 32 cases in each group. The clinical efficacy, hemoglobin (Hb), white blood cell (WBC), platelet (PLT) before and after the treatment, and the adverse reactions during the treatment in the two groups were observed and compared. Result: Compared with the control group, the total effective rate significantly increased in the observation group (81.25% VS 56.25%, P <0.05).Compared with the control group, the total effective rate for TCM syndromes significantly increased in the observation group (96.875% VS 78.125%, P <0.05).Compared with the control group, the levels of Hb (80.32±21.27 VS 69.78±20.13) g · L^-1, WBC (3.92±1.11 VS 3.14±1.08)×10⁹/L and PLT (46.37±14.32 VS 31.08±13.82)×10⁹/L significantly increased in the observation group after the treatment (P <0.05).Compared with the control group, adverse reactions, such as hirsutism (6.25% VS 28.125%), hands shaking (12.50% VS 37.50%) and gingival hyperplasia (6.25% VS 25.00%) significantly reduced in the observation group (P <0.05). Conclusion: Zisui Shengxue capsule shows significant efficacy and less adverse reactions in treating chronic aplastic anemia, and can obviously improve the patients' hemogram indexes. It is worthy of clinical promotion.